Compare KVUE & VEEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVUE | VEEV |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Computer Software: Prepackaged Software |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 28.9B |
| IPO Year | 2023 | 2013 |
| Metric | KVUE | VEEV |
|---|---|---|
| Price | $17.52 | $178.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 26 |
| Target Price | $19.73 | ★ $283.80 |
| AVG Volume (30 Days) | ★ 32.2M | 2.0M |
| Earning Date | 05-19-2026 | 05-29-2026 |
| Dividend Yield | ★ 4.77% | N/A |
| EPS Growth | ★ 40.74 | 34.16 |
| EPS | 0.76 | ★ 3.96 |
| Revenue | ★ $15,124,000,000.00 | $1,104,081,000.00 |
| Revenue This Year | $4.80 | $13.64 |
| Revenue Next Year | $2.52 | $12.67 |
| P/E Ratio | ★ $22.87 | $45.77 |
| Revenue Growth | N/A | ★ 28.05 |
| 52 Week Low | $14.02 | $168.14 |
| 52 Week High | $25.17 | $310.50 |
| Indicator | KVUE | VEEV |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 38.52 |
| Support Level | $17.14 | $169.92 |
| Resistance Level | $17.89 | $184.71 |
| Average True Range (ATR) | 0.31 | 7.38 |
| MACD | -0.19 | 1.11 |
| Stochastic Oscillator | 8.52 | 19.86 |
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.